United Therapeutics vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

United Therapeutics Corporation (UTHR)

Q3 202612 Jul – 2 Oct 2026

▲4▼3

Legal Win and Organ Flights Boost UTHR, but Competition and Analyst Caution Linger

Court Blocks Liquidia's Yutrepia in PH-ILD A Delaware court blocked Liquidia's Yutrepia in PH-ILD, a key lung disease. This protects UTHR's Tyvaso franchise and sent shares up 12.5%.
This legal win directly removes a competitive threat and caused a sharp stock jump.
Manufactured Organs Flown on eVTOL United Therapeutics advanced its organ-delivery story by flying manufactured organs on the first U.S. eVTOL pilot flights, moving closer to its long-term goal of providing transplantable organs.
This milestone supports the company's long-term growth narrative and differentiates it from peers.
Phase 3 Data Supports Two FDA Filings New Phase 3 data supported two FDA filings, potentially expanding UTHR's product labels and driving future revenue growth.
Positive clinical data and regulatory filings are key catalysts for future sales.
Accelerated Buyback Returns $477.6 Million UTHR returned $477.6 million to shareholders via an accelerated buyback, signaling confidence and supporting the stock price.
Buybacks reduce share count and often boost investor sentiment.
Liquidia's Yutrepia Gains PAH Share Liquidia's Yutrepia continues to gain share in PAH, threatening UTHR's Tyvaso franchise. This competitive pressure weighs on the stock.
Ongoing competitive threat to core revenue stream.
Judge Criticizes Deceptive Patent Document A judge criticized UTHR for a deceptive, backdated patent-fight document, raising legal and reputational concerns.
This legal issue could lead to penalties and damage trust.
Goldman Sachs Initiates with Sell Rating Goldman Sachs initiated coverage with a Sell rating, doubting UTHR's 2029 targets. This analyst caution adds pressure on the stock.
Analyst downgrade can influence investor sentiment and stock performance.
New Tresmi Inhaler Could Defend Tyvaso The new Tresmi inhaler could help defend the Tyvaso franchise against competition, but its impact is uncertain and competition remains intense.
Potential positive product but not yet proven, so mixed effect.

September 20265 Aug – 2 Oct 2026

▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.
This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.
New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.
This is a fresh positive catalyst that strengthens the case for two potential new products.
Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.
This is a new capital-return action that directly affects share count and investor sentiment.
Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.
This is a new analyst action that introduces a notable counterweight to the positive patent news.

Latest5 Aug – 2 Oct 2026

▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.
This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.
New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.
This is a fresh positive catalyst that strengthens the case for two potential new products.
Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.
This is a new capital-return action that directly affects share count and investor sentiment.
Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.
This is a new analyst action that introduces a notable counterweight to the positive patent news.

July 202612 Jul – 22 Jul 2026

▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.
New concrete validation of UTHR's organ business and logistics use case.
Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.
Shows the competitive threat to UTHR's main revenue source is growing.
Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.
New legal setback that could affect UTHR's ability to defend its PAH patents.
New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.
New product that may offset competitive and royalty pressures on UTHR's PAH business.

12 Jul – 22 Jul 2026

▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.
New concrete validation of UTHR's organ business and logistics use case.
Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.
Shows the competitive threat to UTHR's main revenue source is growing.
Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.
New legal setback that could affect UTHR's ability to defend its PAH patents.
New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.
New product that may offset competitive and royalty pressures on UTHR's PAH business.

Q2 202617 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

June 202617 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

17 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

Amgen Inc (AMGN)

Q3 20268 Jul – 14 Sep 2026

▲2▼2

Amgen Q3: Pelacarsen Blow Sinks Shares, Recalls and Rival Threats Weigh

Pelacarsen failure casts doubt on Amgen's olpasiran Novartis' heart drug pelacarsen failed, and because Amgen's similar olpasiran works the same way, investors feared it could fail too. Shares fell about 10% and BMO downgraded the stock.
This was the single most severe event of the quarter, directly sinking the share price.
Court blocks Colorado's 70% Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, reducing regulatory risk for Amgen's biggest drug. This removes a threat that could have slashed revenue from a key product.
A major legal win that eased a key overhang on the stock.
Q2 beat and raised guidance, key products grow 26% Amgen's Q2 earnings and revenue beat estimates, and the company raised its full-year guidance. Six key products grew 26%, showing the new drug lineup is driving growth.
Strong financial results and raised outlook support the stock.
Recalls, competition, pipeline setback, cyberattack Corlanor and Sensipar recalls raised quality concerns. Merck's cheaper oral PCSK9 threatens Repatha, Sotyktu may erode Otezla, AMG 513 was discontinued, and a cyberattack triggered lawsuits.
Multiple negative events that weighed on sentiment and future growth prospects.

September 20267 Sep – 14 Sep 2026

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.
This is the main new force driving AMGN down this period.
BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.
Analyst downgrade is a direct new negative catalyst for the stock.
IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.
A major positive pipeline win that offsets some of the Lp(a) pessimism.
FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.
Regulatory win that improves commercial practicality of a growth drug.

Latest7 Sep – 14 Sep 2026

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.
This is the main new force driving AMGN down this period.
BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.
Analyst downgrade is a direct new negative catalyst for the stock.
IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.
A major positive pipeline win that offsets some of the Lp(a) pessimism.
FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.
Regulatory win that improves commercial practicality of a growth drug.

August 202629 Jul – 3 Sep 2026

▲2▼2

Amgen beats Q2, raises guidance, but obesity setback and cyberattack weigh

Q2 earnings beat and guidance raise Amgen reported Q2 adjusted EPS of $6.29 and revenue of $10.05B, beating estimates, and raised its 2026 guidance. Six key growth products grew 26%, reducing reliance on older drugs.
This is a new positive fundamental development that directly supports the stock.
Repatha and Tezspire clinical wins Repatha cut death risk by 20% in a major heart trial, and Tezspire met all goals in an eosinophilic esophagitis study. These results lifted shares to a 52-week high and prompted analyst target hikes.
New clinical data and analyst reactions are key drivers of the stock's move this period.
Obesity drug AMG 513 discontinued Amgen discontinued its obesity drug AMG 513, leaving MariTide trailing Eli Lilly and Novo Nordisk in the lucrative obesity market. This raises concerns about Amgen's competitive position.
This is a new negative event that affects future growth prospects.
Cyberattack and drug-price pressure A July cyberattack exposed patient and proprietary data, triggering a class action investigation. Also, a looming US drug-price agreement with mid-sized biotechs could pressure Medicaid revenue.
These are new risk factors that emerged during the period and could weigh on the stock.

8 Aug – 3 Sep 2026

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.
This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.
Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.
New positive trial results expand a key product's potential, a fresh catalyst for the stock.
US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.
This is a new regulatory risk that could directly affect Amgen's pricing and profits.
Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.
This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

29 Jul – 6 Aug 2026

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.
This is the main new positive event that drove the stock up over 5% this period.
Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.
It explains the underlying strength behind the earnings beat and why the stock rose.
Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.
It is a new negative event that could pressure the stock and is important for a balanced view.
Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.
It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 20268 Jul – 23 Jul 2026

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.
This is a major new legal win that directly supports Amgen's revenue outlook.
Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.
New recalls create fresh regulatory and reputational risk that can hurt the stock.
New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.
A new lower-priced competitor directly challenges a key Amgen growth drug.
Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.
New competitive data shows a direct threat to an existing Amgen product.

8 Jul – 23 Jul 2026

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.
This is a major new legal win that directly supports Amgen's revenue outlook.
Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.
New recalls create fresh regulatory and reputational risk that can hurt the stock.
New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.
A new lower-priced competitor directly challenges a key Amgen growth drug.
Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.
New competitive data shows a direct threat to an existing Amgen product.

Q2 202618 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.

June 202618 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.

18 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.